- Previous Close
16.17 - Open
16.22 - Bid 16.99 x 100
- Ask 17.16 x 100
- Day's Range
15.50 - 17.30 - 52 Week Range
14.93 - 45.00 - Volume
271,112 - Avg. Volume
383,432 - Market Cap (intraday)
463.195M - Beta (5Y Monthly) 2.64
- PE Ratio (TTM)
-- - EPS (TTM)
-2.33 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
79.47
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
arcturusrx.comRecent News: ARCT
View More
Performance Overview: ARCT
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARCT
View MoreValuation Measures
Market Cap
438.00M
Enterprise Value
230.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.06
Price/Book (mrq)
1.67
Enterprise Value/Revenue
1.62
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-39.05%
Return on Assets (ttm)
-12.15%
Return on Equity (ttm)
-23.12%
Revenue (ttm)
160.4M
Net Income Avi to Common (ttm)
-62.64M
Diluted EPS (ttm)
-2.33
Balance Sheet and Cash Flow
Total Cash (mrq)
237.18M
Total Debt/Equity (mrq)
11.24%
Levered Free Cash Flow (ttm)
-40.26M
Research Analysis: ARCT
View MoreCompany Insights: ARCT
ARCT does not have Company Insights
Research Reports: ARCT
View MoreDaily – Vickers Top Buyers & Sellers for 06/17/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/29/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/13/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.